182 related articles for article (PubMed ID: 9676646)
1. Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin).
Humbert M; Sanchez O; Fartoukh M; Jagot JL; Sitbon O; Simonneau G
Chest; 1998 Jul; 114(1 Suppl):80S-82S. PubMed ID: 9676646
[No Abstract] [Full Text] [Related]
2. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
Humbert M; Sanchez O; Fartoukh M; Jagot JL; Le Gall C; Sitbon O; Parent F; Simonneau G
Eur Respir J; 1999 Jun; 13(6):1351-6. PubMed ID: 10445611
[TBL] [Abstract][Full Text] [Related]
3. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension.
Mikhail G; Gibbs J; Richardson M; Wright G; Khaghani A; Banner N; Yacoub M
Eur Heart J; 1997 Sep; 18(9):1499-504. PubMed ID: 9458458
[TBL] [Abstract][Full Text] [Related]
5. Nebulized prostacyclin for pulmonary hypertension: a step in the right direction.
Wang A; Bashore TM
Eur Heart J; 1997 Sep; 18(9):1364-5. PubMed ID: 9458437
[No Abstract] [Full Text] [Related]
6. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
[TBL] [Abstract][Full Text] [Related]
7. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
8. [Pulmonary hypertension associated with connective tissue diseases].
Sanchez O; Humbert M; Sitbon O; Nunes H; Garcia G; Simonneau G
Rev Med Interne; 2002 Jan; 23(1):41-54. PubMed ID: 11859694
[TBL] [Abstract][Full Text] [Related]
9. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
10. Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.
Castro PF; Bourge RC; McGiffin DC; Benza RL; Fan P; Pinkard NB; McGoon MD
Chest; 1998 Jul; 114(1):334-6. PubMed ID: 9674493
[TBL] [Abstract][Full Text] [Related]
11. [Pulmonary arterial hypertension in connective tissue diseases].
Degano B
Rev Mal Respir; 2006 Dec; 23(6):746-8. PubMed ID: 17886350
[No Abstract] [Full Text] [Related]
12. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
13. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.
McLaughlin VV; Genthner DE; Panella MM; Hess DM; Rich S
Ann Intern Med; 1999 May; 130(9):740-3. PubMed ID: 10357693
[TBL] [Abstract][Full Text] [Related]
14. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure.
Reddy MT; Patel H; Ventura HO
Congest Heart Fail; 2008; 14(5):285-6. PubMed ID: 18983294
[No Abstract] [Full Text] [Related]
15. Ventilation/perfusion ratios in pulmonary arterial hypertension: effects of IV and inhaled prostacyclin derivatives.
Bratel T; Lagerstrand L; Brodin LA; Nowak J; Randmaa I
Chest; 2005 Dec; 128(6 Suppl):615S-616S. PubMed ID: 16373868
[No Abstract] [Full Text] [Related]
16. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol.
Ramsay MA; Spikes C; East CA; Lynch K; Hein HA; Ramsay KJ; Klintmalm GB
Anesthesiology; 1999 Jan; 90(1):299-301. PubMed ID: 9915339
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic evaluation of continuous intravenous epoprostenol.
Chaumais MC; Jobard M; Huertas A; Vignand-Courtin C; Humbert M; Sitbon O; Rieutord A; Montani D
Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1587-98. PubMed ID: 21077785
[TBL] [Abstract][Full Text] [Related]
18. Epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
Botney M
N Engl J Med; 1998 Jun; 338(24):1773-4. PubMed ID: 9625639
[No Abstract] [Full Text] [Related]
19. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
Frost AE; Quiñones MA; Zoghbi WA; Noon GP
J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
[TBL] [Abstract][Full Text] [Related]
20. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
